EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long-Term Outcomes in Radioiodine-Resistant Follicular Cell-Derived Thyroid Cancers Treated with [ 177 Lu]Lu-DOTAGA.FAPi Dimer Therapy

Sanjana Ballal, Madhav Prasad Yadav, Swayamjeet Satapathy, Frank Roesch, Kunal R Chandekar, Marcel Martin, Mohammad Shakir, Shipra Agarwal iD, Sameer Rastogi, Euy Sung Moon, Chandrasekhar Bal

Thyroid® · 2025

DOI: 10.1089/thy.2024.0229 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thyroid®, 2025. Verfasst von Sanjana Ballal und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Adenocarcinoma, Follicular, Iodine Radioisotopes, Octreotide. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

The study aimed to analyze the long-term outcomes of [ 177 Lu]Lu-DOTAGA.FAPi dimer therapy in individuals diagnosed with radioiodine-resistant (RAI-R) follicular cell-derived thyroid cancer. Materials and Methods: In this retrospective study, 73 patients with RAI-R follicular thyroid carcinoma who had undergone multiple lines of previous treatments were included. Following [ 68 Ga]Ga-DOTA.SA.FAPi positron emission tomography–computed tomography scan, among the 73 patients, 65 received [ 177 Lu]Lu-DOTAGA.FAPi dimer monotherapy with a median activity of 5.5 GBq per cycle at 8-week intervals. The remaining eight patients underwent tandem [ 177 Lu]Lu/[ 225 Ac]Ac-DOTAGA.FAPi dimer therapy, consisting of a median of two cycles of [ 177 Lu]Lu-DOTAGA.FAPi dimer followed by one cycle of [ 225 Ac]Ac-DOTAGA.FAPi dimer, also at 8-week intervals. The primary endpoint included progression-free survival (PFS) and overall survival (OS). Secondary endpoints included PERCIST criteria response assessment and safety assessment according to Common Terminology Criteria for Adverse Events (V5.0).

Results

We enrolled 37 female and 36 male patients, with a mean age of 54.3 years (range: 27 − 80 years). The patients received a median cumulative activity of 22.2 GBq (range, 4 GBq–55.5 GBq) of [ 177 Lu]Lu-DOTAGA-FAPi dimer over one to nine cycles, with a median of three cycles. Among 73 patients, 20 died and 16 deaths were due to thyroid cancer. Nineteen patients experienced disease progression, with an estimated median PFS of 29 months [CI 14–34 months]. The estimated median OS was 32 months [CI 21–40 months]. Four patients (5.4%) encountered grade III anemia, primarily linked to bone metastasis in three cases and neck tumor mass bleed in one. Grade III thrombocytopenia occurred in three patients (4%). No grade III renal or hepatotoxicity was observed.

Conclusion

In this study, [ 177 Lu]Lu-DOTAGA.FAPi dimer therapy showed promising safety and efficacy in aggressive, radioiodine-resistant thyroid cancer, achieving a median PFS and OS of 29 and 32 months, respectively, with manageable adverse events. Confirmation of our findings is needed from prospective clinical trials comparing [ 177 Lu]Lu-DOTAGA.FAPi dimer therapy to other treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsAdenocarcinoma, FollicularIodine RadioisotopesOctreotideRadiopharmaceuticalsHumansFemaleMaleMiddle AgedRetrospective StudiesAgedAdultTreatment OutcomeLutetiumAged, 80 and over

Stichwörter der Autor:innen

[177Lu]Lu-DOTAGA.FAPi dimerfibroblast activation protein inhibitorsradioiodine refractory differentiated thyroid cancer

Substanzen

Iodine RadioisotopesOctreotideLutetiumRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Department of Chemistry-TRIGA, Johannes Gutenberg University, Mainz, Germany.
  • Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.
  • Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.

ORCID-Profile: Shipra Agarwal

Zitieren

APA

Ballal, S., Yadav, M. P., Satapathy, S., Roesch, F., Chandekar, K. R., Martin, M., Shakir, M., Agarwal, S., Rastogi, S., Moon, E. S., & Bal, C. (2025). Long-Term Outcomes in Radioiodine-Resistant Follicular Cell-Derived Thyroid Cancers Treated with [ 177 Lu]Lu-DOTAGA.FAPi Dimer Therapy. Thyroid®. https://doi.org/10.1089/thy.2024.0229

Vancouver

Ballal S, Yadav MP, Satapathy S, Roesch F, Chandekar KR, Martin M, et al. Long-Term Outcomes in Radioiodine-Resistant Follicular Cell-Derived Thyroid Cancers Treated with [ 177 Lu]Lu-DOTAGA.FAPi Dimer Therapy. Thyroid®. 2025. doi:10.1089/thy.2024.0229

BibTeX
@article{Ballal2025,
  author = {Ballal, Sanjana and Yadav, Madhav Prasad and Satapathy, Swayamjeet and Roesch, Frank and Chandekar, Kunal R and Martin, Marcel and Shakir, Mohammad and Agarwal, Shipra and Rastogi, Sameer and Moon, Euy Sung and Bal, Chandrasekhar},
  title = {Long-Term Outcomes in Radioiodine-Resistant Follicular Cell-Derived Thyroid Cancers Treated with [ 177 Lu]Lu-DOTAGA.FAPi Dimer Therapy},
  journal = {Thyroid®},
  year = {2025},
  doi = {10.1089/thy.2024.0229}
}
Kostenlos starten →